Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Actinium Pharmaceuticals (ATNM) Shares Outstanding (2021 - 2025)

Actinium Pharmaceuticals (ATNM) has disclosed Shares Outstanding for 7 consecutive years, with $31.2 million as the latest value for Q3 2024.

  • On a quarterly basis, Shares Outstanding rose 13.8% to $31.2 million in Q3 2024 year-over-year; TTM through Sep 2024 was $31.2 million, a 13.8% increase, with the full-year FY2023 number at $27.6 million, up 7.63% from a year prior.
  • Shares Outstanding was $31.2 million for Q3 2024 at Actinium Pharmaceuticals, up from $30.6 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $31.2 million in Q3 2024 to a low of $19.2 million in Q1 2021.
  • A 4-year average of $25.4 million and a median of $25.7 million in 2022 define the central range for Shares Outstanding.
  • Peak YoY movement for Shares Outstanding: increased 17.92% in 2022, then rose 7.63% in 2023.
  • Actinium Pharmaceuticals' Shares Outstanding stood at $22.1 million in 2021, then rose by 15.94% to $25.7 million in 2022, then increased by 7.63% to $27.6 million in 2023, then increased by 12.89% to $31.2 million in 2024.
  • Per Business Quant, the three most recent readings for ATNM's Shares Outstanding are $31.2 million (Q3 2024), $30.6 million (Q2 2024), and $29.4 million (Q1 2024).